Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of cytochalasin H in preparation of Parkinson's disease resistant drugs

A Parkinson's disease compound technology, applied in the application field of the cytochalasin compound cytochalasin H in the preparation of anti-Parkinson's disease drugs, can solve the problems that the application of cytochalasin H has not yet been discovered, and achieve low effective drug concentration and broad application prospects Effect

Inactive Publication Date: 2014-05-28
YANGZHOU UNIV
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The cytochalasin compound cytochalasin H has a variety of physiological and biochemical activities, but the application of cytochalasin H in neuroprotective drugs against Parkinson's disease has not been found so far

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of cytochalasin H in preparation of Parkinson's disease resistant drugs
  • Application of cytochalasin H in preparation of Parkinson's disease resistant drugs
  • Application of cytochalasin H in preparation of Parkinson's disease resistant drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Example 1.MPP + Replicate the dose-effect and time-effect relationship of PD cell model

[0026] Experimental instruments and materials:

[0027] PB11OS electronic balance (Sartorius, Germany);

[0028] SW-CJ-1F ultra-clean bench (Suzhou Purification Equipment Co., Ltd.);

[0029] Forma3111 water-jacketed carbon dioxide incubator (Thermo / USA);

[0030] ELX-800UV microplate reader (BIO-TEK, USA);

[0031] Rat pheochromocytoma PCl2 cells (Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences);

[0032] Newborn bovine serum (Hangzhou Sijiqing Bioengineering Materials Co., Ltd.);

[0033] DMEM (GIBCO Corporation);

[0034] MPP + (SIGMA-Aldrich);

[0035] MTT (AMROSCO Corporation);

[0036] DMSO (AMROSCO Corporation).

[0037] experimental method:

[0038] PC12 cells were cultured in DMEM medium containing 10% newborn bovine serum in CO 2 Incubator (37°C, 5% CO 2 , with a relative humidity of 95%), passaging every 3-4 days. Take the cells in...

Embodiment 2

[0041] Example 2.cytochalasin H to MPP+ Effects of Induced PC12 Cell Injury

[0042] Experimental instruments and materials:

[0043] PB11OS electronic balance (Sartorius, Germany);

[0044] SW-CJ-1F ultra-clean bench (Suzhou Purification Equipment Co., Ltd.);

[0045] Forma3111 water-jacketed carbon dioxide incubator (Thermo / USA);

[0046] ELX-800UV microplate reader (BIO-TEK, USA);

[0047] Rat pheochromocytoma PCl2 cells (Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences);

[0048] Cytochalasin H (can be purchased from Santa Cruz Biotechnology or Sigma-Aldrich; it can also be isolated from the solid fermentation product of endophyte Phomopsis sp. IFB-E060 (GenBank No.: GU989315). Isolation and identification of endophytic strain IFB-E060 And the extraction, separation and structural identification of fermentation and compounds can be carried out with reference to the literature [Xu S, et al. Chem Biodivers2009, 6(5):739-745]);

[0049] Newborn bo...

Embodiment 3

[0071] Example 3.cytochalasin H to MPP + Effect of Inducing PC12 Cell Apoptosis

[0072] Experimental instruments and materials:

[0073] PB11OS electronic balance (Sartorius, Germany);

[0074] SW-CJ-1F ultra-clean bench (Suzhou Purification Equipment Co., Ltd.);

[0075] OPTIPHOT-2 fluorescence microscope (NIKON, Japan);

[0076] XDS-1B inverted biological microscope (Chongqing Optical Instrument Co., Ltd.);

[0077] Forma3111 water-jacketed carbon dioxide incubator (Thermo / USA);

[0078] Flow cytometry (FACSAria, BD, USA);

[0079] Rat pheochromocytoma PCl2 cells (Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences);

[0080] cytochalasin H (same as Example 2);

[0081] DMSO (AMROSCO Corporation);

[0082] Newborn bovine serum (Hangzhou Sijiqing Bioengineering Materials Co., Ltd.);

[0083] DMEM (GIBCO Corporation);

[0084] MPP + (SIGMA-Aldrich);

[0085] R-(-)-Deprenyl HCl (Enzo Life Sciences, Inc.);

[0086] AnnexinⅤ-FITC Cell Apoptosis ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to new application of cytochalasin H in pharmacy, and particularly relates to the application of the cytochalasin H in preparation of Parkinson's disease resistant nerve-protective drugs. A series of in-vitro tests certificates that the cytochalasin H has significant protective effects on PC12 cellular damage induced by MPP +, and can be used to develop the Parkinson's disease resistant drugs.

Description

technical field [0001] The present invention relates to a new pharmaceutical application of a compound—cytochalasin H, a cytochalasin compound, in particular to the application of cytochalasin H in the preparation of neuroprotective drugs against Parkinson's disease. Background technique [0002] Parkinson's disease (Parkinson's disease, PD) is a common degenerative disease of the central nervous system. It is caused by progressive and selective loss of striatal dopamine (dopamine, DA) neural pathway. At present, clinical treatment mainly uses dopamine drugs such as levodopa. These drugs can only relieve symptoms in the early stage of the disease, but are unable to alleviate the basic process of PD and the progressive loss of DA neurons. With the prolongation of medication time, the efficacy of the drug gradually decreases, and severe side effects often occur, seriously affecting the patient's compliance and quality of life. Therefore, there is an urgent need for clinical ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/403A61P25/16
Inventor 申丽葛晓群颜玉文魏中琦鞠婧婧陈琴吕丹
Owner YANGZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com